Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2020 Q1 earnings Read more ...
Daiichi Sankyo ( OTCPK:DSKYF ): FY GAAP EPS of ¥198.80. Revenue of ¥981.79B (+5.6% Y/Y) Press Release More news on: Daiichi Sankyo Company, Limited, Earnings news and commentary, Financial stocks news,
Ultragenyx (NASDAQ: RARE ) inks an agreement with Daiichi Sankyo ( OTCPK:DSKYF ) for its proprietary AAV-based gene therapy manufacturing technologies. More news on: Ultragenyx Pharmaceutical Inc., Daiichi Sankyo Company, Limited, Daiichi Sankyo Company, Limited, Healthcare stocks news, ...
Daiichi Sankyo ( OTCPK:DSKYF ) and collaboration partner AstraZeneca ( AZN -0.9% ) announce positive topline results from a pivotal Phase 2 clinical trial, DESTINY-Gastric01 , evaluating HER-targeted antibody-drug conjugate (ADC) DS-8201 in patients with HER2-positive unresectable/metas...
Company Overview Puma Biotechnology ( PBYI ) is a pharmaceutical company producing drugs used in cancer treatments. Their main product is Nerylinx, a compound used to treat breast cancer, specifically those that are HER-2 positive. The company has seen much volatility in terms of earning...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
AstraZeneca (NYSE: AZN ) and collaboration partner Daiichi Sankyo ( OTCPK:DSKYF ) announce positive results from a pivotal, single-arm, open-label Phase 2 clinical trial, DESTINY-Breast01 , evaluating trastuzumab deruxtecan (DS-8201), an HER2-targeting antibody-drug conjugate, in patients...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with this Read more ...
Daiichi Sankyo ( OTCPK:DSKYF ) has submitted a marketing application in Japan seeking approval to use SAKIGAKE-tagged antibody-drug conjugate (ADC) [fam-] trastuzumab deruxtecan (DS-8201) to treat patients with HER2-positive metastatic breast cancer. More news on: Daiichi Sankyo Company,...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...